01578nas a2200217   4500000000100000008004100001260003400042653005700076653002700133653002100160653001500181100001100196700001600207700001100223245011500234856009200349300001200441490000700453520087500460022002501335       2020                            d  bOxford University Press (OUP)10aPublic Health, Environmental and Occupational Health10aHealth(social science)10aGeneral Medicine10aIvermectin1 aWeil G1 aJacobson JA1 aKing J00aA triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery  uhttps://academic.oup.com/inthealth/article-pdf/13/Supplement_1/S60/35056130/ihaa046.pdf  aS60-S640 v133 a<jats:title>Abstract</jats:title>
               <jats:p>The Global Programme to Eliminate Lymphatic Filariasis (LF) is using mass drug administration (MDA) of antifilarial medications to treat filarial infections, prevent disease and interrupt transmission. Almost 500 million people receive these medications each year. Clinical trials have recently shown that a single dose of a triple-drug combination comprised of ivermectin, diethylcarbamazine and albendazole (IDA) is dramatically superior to widely used two-drug combinations for clearing larval filarial parasites from the blood of infected persons. A large multicenter community study showed that IDA was well-tolerated when it was provided as MDA. IDA was rapidly advanced from clinical trial to policy and implementation; it has the potential to accelerate LF elimination in many endemic countries.</jats:p>  a1876-3413, 1876-3405